Research & Education

Need for national Canadian strategy for EGFR testing

Testing dropped once funding from pharmaceutical industry was discontinued

DENVER – Significant advances have taken place in the management of patients with advanced and metastatic non–small-cell lung cancer (NSCLC) over t

CAP IASLC AMP Molecular Testing Guideline

Leading Health Care Organizations issue Guideline recommendations for Molecular Testing and Targeted Therapies

The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular P

Comparable patterns of failure between SBRT, lobectomy or pneumonectomy for stage I non-small cell lung cancer

Researchers report need to enroll patients in randomized trials

DENVER – For patients with medically operable clinical stage I non–small-cell lung cancer (NSCLC), lobectomy or pneumonectomy is the standard appro

Patients with EGFR exon 20 insertions have poorer prognosis

Researchers conclude this population needs targeted therapy

DENVER – Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non–small-cell lung canc

EGFR mutation not prognostic factor in non-small cell lung cancer

Smoking status seems to be most important prognostic factor

DENVER – Recent studies have demonstrated that molecular-targeted agents, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor

Greater representation of elderly patients in Phase III trials needed

Better representation can improve evidence-based treatment

DENVER – The median age of patients diagnosed with advanced non–small-cell lung cancer (NSCLC) has steadily increased over the recent years and is